Difference between revisions of "Belantamab mafodotin (Blenrep)"
m |
|||
Line 9: | Line 9: | ||
==Patient drug information== | ==Patient drug information== | ||
− | *[https:// | + | *[https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Blenrep/pdf/BLENREP-PI-MG.PDF Belantamab mafodotin (Blenrep) package insert]<ref>[https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Blenrep/pdf/BLENREP-PI-MG.PDF Belantamab mafodotin (Blenrep) Package Insert]</ref> |
==Also known as== | ==Also known as== |
Revision as of 16:40, 27 May 2021
Mechanism of action
From the NCI Drug Dictionary: An antibody-drug conjugate (ADC) consisting of belantamab, an afucosylated, humanized monoclonal antibody, directed against the B-cell maturation antigen (BCMA), conjugated to mafodotin, an auristatin analogue and microtubule inhibitor monomethyl auristatin phenylalanine (MMAF), with potential antineoplastic activity. Upon administration of belantamab mafodotin, the anti-BCMA antibody moiety selectively binds to BCMA on tumor cell surfaces. Upon internalization, the MMAF moiety binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces tumor cell apoptosis. In addition, belantamab mafodotin-blmf induces antibody-dependent cellular cytotoxicity (ADCC). Altogether, this results in the inhibition of cellular proliferation in tumor cells that overexpress BCMA.
Diseases for which it is used
History of changes in FDA indication
- 8/5/2020: Approved for adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. (Based on DREAMM-2)
Patient drug information
Also known as
- Code name: GSK2857916
- Generic name: belantamab mafodotin-blmf
- Brand name: Blenrep